Prospective evaluation of patients with primary CNS Lymphoma undergoing high dose consolidation chemotherapy with LACE.

Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients with histologically proven PCNSL and planned for ASCT
•2. Age > 18 years and less than 65 years
•3. ECOG PS <4
•4.Adequate bone marrow function with absolute leukocytes > 2000/mm3, neutrophil count (ANC) > 1000/mm3, hemoglobin > 8 g/dl and platelets > 100 000/mm3
•5.Adequate liver function with Serum SGOT/AST or SGPT/ALT < 3.0 X Upper Limit of Normal ULN ; bilirubin < 1.5 X LNS
•6. Creatinine clearance > 60 ml/min.
•7.Adequate cardiac function (LVEF more than 45%)
•8.Adequate lung function (DLCO more than 50%)
•9. Able to understand and sign informed consent

•Chemo-refractory disease
•2.HIV infection
•3.Active hepatitis B or C
•4.Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

发起方